FDA turns away filing for Celgene’s MS drug

1st March 2018 Uncategorised 0

US regulators are refusing to file Celgene’s application to market its experimental multiple sclerosis therapy ozanimod.

More: FDA turns away filing for Celgene’s MS drug
Source: News